Introduction {#s1}
============

The pictorial description in 1962 of the aggregation of blood platelets by ADP, using a novel device called the Born aggregometer ([@B8]), paved the way to quantitative assessment of platelet inhibition *in vitro* and *ex vivo* (reviewed by [@B9]). However, the possibility of establishing a mechanistic link between the inhibition of platelet prostanoid formation by aspirin ([@B79]) and inhibition of platelet aggregation had to wait the discovery of a novel pro-aggregating and vasoconstrictor prostanoid, thromboxane (TX)A~2~, as the major arachidonic acid derivative in human platelets ([@B36]). This discovery allowed the development of appropriate analytical tools to investigate platelet TXA~2~ biosynthesis and its inhibition by aspirin in human health and disease (reviewed by [@B9]). TXA~2~ is a pro-thrombotic, chemically unstable prostanoid, mostly synthesized *via* cyclooxygenase (COX)-1 and released by activated platelets (reviewed by [@B21]). Two different biomarkers were characterized independently to assess TXA~2~ biosynthesis *ex vivo*, i.e., whole-blood TXB~2~ production ([@B55]), and *in vivo*, i.e., urinary TXB~2~ metabolite excretion ([@B70]) ([**Figure 1**](#f1){ref-type="fig"}). By raising a specific antibody against TXB~2~, the chemically stable and biologically inactive hydrolysis product of TXA~2~, we were able to measure the time-dependent synthesis and release of platelet TXA~2~ induced by endogenous thrombin generated during whole-blood clotting and to demonstrate its suppression by low doses of aspirin ([@B55]). The pioneering work of John Oates and his associates at Vanderbilt University was responsible for the development of a non-invasive approach to investigating prostanoid biosynthesis in man, based on the measurements of urinary prostanoid metabolites. In 1981, they reported the conversion of systemically infused TXB~2~ into 20 enzymatic derivatives, which were identified in the urine of a single healthy volunteer by gas chromatography/mass spectrometry (GC/MS) ([@B70]). The availability of these analytical tools paved the way for investigating TXA~2~ biosynthesis in health and disease and its selective, cumulative inhibition by low-dose aspirin, that eventually led to its development as an antiplatelet drug for the treatment and prevention of atherothrombosis (reviewed by [@B53]).

![Assessment of platelet thromboxane (TX)A~2~ biosynthesis *ex vivo* and *in vivo*. The left panel depicts the chain of enzymatic reactions triggered by thrombin generation during whole-blood clotting, and the resulting formation of very large amounts of TXB~2~ (the stable hydration product of TXA~2~) that can be easily measured in serum as a sensitive and specific index of platelet COX-1 activity. The right panel depicts the metabolic fate of TXA~2~*in vivo* and the calculated rate of its production in healthy subjects on the basis of TXB~2~ infusions and measurement of its major urinary metabolites, 11-dehydro-TXB~2~ and 2,3-dinor-TXB~2~. The latter represent a non-invasive index of platelet activation *in vivo*. Modified and redrawn from [@B62].](fphar-10-01244-g001){#f1}

This article reviews the main findings of four decades of clinical investigation based on these analytical approaches, focusing on the measurement of TXA~2~ metabolites *in vivo* and *ex vivo* as indexes of platelet activation and COX-1 activity, respectively, with emphasis on the authors' contribution to the resulting pathophysiological and pharmacological developments.

Urinary Thromboxane Metabolite Excretion as a Non-Invasive Biomarker of Platelet Activation *In Vivo* {#s2}
=====================================================================================================

In 1981, Roberts et al. reported the GC/MS characterization of 20 enzymatic metabolites of systemically infused \[^3^H~8~\]TXB~2~. Two major series of metabolites were identified based on a ring structure. One series retained the original TXB~2~ hemiacetal ring and included two metabolites, 2,3-dinor-TXB~2~ (the most abundant urinary metabolite) and 2,3,4,5-tetranor-TXB~2~, which were products of beta-oxidation ([@B70]). The second group of derivatives was formed as a result of dehydrogenation of the hemiacetal alcohol group at C-11, and included 16 metabolites ([@B70]). Among the compounds resulting from this single transformation, 11-dehydro-TXB~2~ was the most abundant urinary metabolite ([@B70]). In their seminal paper in the *Journal of Biological Chemistry*, Roberts et al. accurately predicted the potential value of this analytical approach: "Since thromboxanes are released in substantial quantities from aggregating platelets, quantification of *in vivo* thromboxane production may provide a means to assess *in vivo* platelet aggregation and lead to a better understanding of the role of platelets in the pathophysiology of many cardiovascular diseases. It may also provide a means to assess the *in vivo* efficacy of anti-platelet drug therapy" ([@B70]). Important limitations of this study were represented by a single high rate of TXB~2~ infusion and a single healthy subject being infused, precluding assessment of the linearity of conversion of TXB~2~ into its major enzymatic derivatives, as well as of the interindividual variability in the prevalence of the two main pathways of its metabolic transformation.

Together with Garret FitzGerald and Ian Blair, we reexamined the metabolic fate of TXB~2~ entering the systemic circulation, by measuring the urinary excretion of 2,3-dinor-TXB~2~ during the infusion of exogenous TXB~2~, in four aspirin-pretreated healthy volunteers randomized to receive 6-h i.v. infusions of vehicle alone and TXB~2~ at 0.1, 1.0, and 5.0 ng·kg^−1^·min^−1^ ([@B56]). Plasma TXB~2~ and urinary 2,3-dinor-TXB~2~ were measured before, during, and up to 24 h after the infusions and in aspirin-free periods. Aspirin treatment suppressed baseline urinary 2,3-dinor-TXB~2~ excretion by 80%, consistent with a predominant platelet source of the parent compound. The fractional excretion of 2,3-dinor-TXB~2~ was independent of the rate of TXB~2~ infusion, over a 50-fold dose range, and averaged 5.3% ± 0.8% ([@B56]). Insertion of 2,3-dinor-TXB~2~ excretion rates measured in aspirin-free periods into the linear relationship between the doses of infused TXB~2~ and the amounts of metabolite excreted in excess of control values permitted estimation of the rate of entry of endogenous TXB~2~ into the circulation as 0.11 ng·kg^−1^·min^−1^ ([@B56]). Upon discontinuing TXB~2~ infusion, its rate of disappearance from the systemic circulation was linear over the first 10 min with an apparent half-life of 7 min. This resulted in a maximal estimate of the plasma concentration of endogenous TXB~2~ of 2.0 pg/ml, i.e., much lower than had been previously reported ([@B56]). This finding argued for a local nature of TXA~2~ synthesis and action, as previously suggested for prostacyclin (PGI~2~) ([@B30]). Similar to the endothelial synthesis of PGI~2~, the maximal TXA~2~ biosynthetic capacity of human platelets greatly exceeds its actual production *in vivo*. Thus, the platelets of 1 ml of whole blood clotted for 1 h *in vitro* can synthesize and release a similar amount of TXB~2~ as that secreted into the systemic circulation *in vivo* during the same time ([@B55]; [@B56]) ([**Figure 1**](#f1){ref-type="fig"}), a finding that may help explain the unusual requirement for greater than 97% inhibition of TXA~2~ biosynthetic capacity to maximally inhibit TXA~2~-dependent platelet function ([@B67]; [@B78]) (see below).

However, because of obvious safety concerns, it had not been possible to investigate the metabolic fate of TXA~2~ in humans, and it remained to be determined whether the enzymatic transformation of TXB~2~ to its major urinary metabolites accurately reflected TXA~2~ metabolism *in vivo*. Thus, together with Joe Rokach and his colleagues at Merck Frosst Research Laboratories, [@B52] compared the metabolic handling of exogenously infused TXA~2~ and TXB~2~ in the cynomolgus monkey. The main finding of this study was that TXA~2~ and TXB~2~ are metabolized to 2,3-dinor-TXB~2~ and 11-dehydro-TXB~2~ with similar fractional conversion rates, thereby suggesting that TXA~2~ is hydrolyzed non-enzymatically to TXB~2~ prior to enzymatic degradation *via* the beta-oxidation and 11-OH-dehydrogenase pathways, and that the resulting urinary metabolites provide a quantitative index of TXA~2~ biosynthesis *in vivo* ([@B52]).

Because previous estimates of the rate of entry of TXB~2~ into the human systemic circulation had been based on monitoring the beta-oxidation pathway of TXB~2~ metabolism ([@B56]), [@B16] went on to measure the urinary excretion of immunoreactive 11-dehydro-TXB~2~ and 2,3-dinor-TXB~2~ ([@B15]) during the infusion of exogenous TXB~2~ over a 50-fold dose range in healthy volunteers, with the same protocol of the previous study ([@B56]). The fractional elimination of both metabolites was independent of the rate of TXB~2~ infusion and averaged 6.0% to 7.0%, demonstrating that urinary 11-dehydro-TXB~2~ is at least as abundant a conversion product of exogenously infused TXB~2~ as 2,3-dinor-TXB~2~ ([@B16]) Furthermore, the study of [@B15] showed that this analytical approach could detect changes in the urinary excretion of immunoreactive 11-dehydro-TXB~2~ associated with simulated short-term increases of TXB~2~ release into the human circulation ([@B15]).

Transient increases in the excretion of 2,3-dinor-TXB~2~ and 11-dehydro-TXB~2~ were described in patients with acute coronary syndromes and interpreted as reflecting repeated episodes of platelet activation ([@B32]; [@B85]). Transient changes in TXA~2~ biosynthesis detected in patients with unstable angina were accompanied by concomitant increases in PGI~2~ biosynthesis, as reflected by urinary 2,3-dinor-6-keto-PGF~1α~ excretion, suggesting a counter-regulatory endothelial activation in this setting ([@B32]). In contrast, patients with chronic stable angina did not display increased TXA~2~ biosynthesis, both under resting conditions and following exercise-induced myocardial ischemia ([@B32]). Biochemical evidence of episodic platelet activation in the setting of acute coronary syndromes was consistent with the post-mortem findings of Michael Davies and Erling Falk that suggested dynamic thrombotic events occurring over a disrupted plaque in the coronary vessels of patients dying after a diagnosis of unstable angina (reviewed by [@B29]; [@B21]). These results provided a rationale for testing the efficacy and safety of low-dose aspirin in acute coronary syndromes, a clinical setting in which antiplatelet therapy reduced the risk of major atherothrombotic complications by approximately 50% (reviewed by [@B58]). Episodic increases in TXB~2~ metabolite excretion were also characterized in patients with acute ischemic stroke ([@B38]; [@B84]), though with a lower frequency and shorter duration than in acute coronary syndromes ([@B32]; [@B85]), perhaps reflecting the heterogeneity of mechanisms responsible for ischemic stroke ([@B1]). Low-dose aspirin (50 mg daily) largely suppressed 11-dehydro-TXB~2~ excretion in this setting, reflecting the predominant platelet origin of TXA~2~ biosynthesis ([@B38]). Enhanced platelet activation was independently associated with stroke severity on admission ([@B84]). Patients with a transient ischemic attack were characterized by infrequent episodes of platelet activation, suggesting that enhanced TXA~2~ biosynthesis was not secondary to cerebral ischemia ([@B38]).

Persistent platelet activation, as reflected by persistently enhanced urinary excretion of TXB~2~ metabolites, was reported by different Groups in patients with a variety of cardiovascular risk factors that accelerate atherogenesis, including cigarette smoking ([@B47]), type-2 diabetes mellitus ([@B18]), hypercholesterolemia ([@B19]), homozygous homocystinuria ([@B25]), and hypertension ([@B44]). Because enhanced urinary excretion of 11-dehydro-TXB~2~ in diabetes mellitus might reflect either an abnormality in the biosynthesis of TXA~2~ or a shift in its metabolic fate through the two main enzymatic pathways of degradation, [@B18] investigated the fractional conversion of infused TXB~2~ to urinary 11-dehydro-TXB~2~ in subjects with type-2 diabetes mellitus. Their finding of a linear conversion of infused TXB~2~ to urinary 11-dehydro-TXB~2~ over a 50-fold range of infusion rates, with a fractional elimination similar to that previously described in healthy subjects ([@B16]), was consistent with enhanced excretion of 11-dehydro-TXB~2~ reflecting a change in the biosynthesis of TXA~2~ rather than an alteration in its enzymatic transformations ([@B18]).

Urinary prostanoid metabolites, such as 11-dehydro-TXB~2~, do not reflect a specific site of prostanoid biosynthesis. To characterize the potential platelet versus non-platelet sources of TXA~2~ biosynthesis, [@B18] used the unique property of aspirin to produce selective, cumulative acetylation of platelet cyclooxygenase (COX)-1 when it is given in low doses once daily ([@B51]). Renal COX-isozymes, which have been involved in enhanced TXA~2~ production in patients with systemic lupus erythematosus ([@B57]), are not inhibited by low-dose aspirin to any detectable extent ([@B51]; [@B66]). The profound reduction in urinary 11-dehydro-TXB~2~ excretion that was found in subjects with type-2 diabetes mellitus after they received 50 mg of aspirin daily for 1 week and the platelet turnover-dependent return to a pre-treatment excretion rate over the next 10 days following aspirin discontinuation were consistent with a prevailing role for platelets as the source of TXA~2~ biosynthesis in this setting ([@B18]).

Persistently enhanced urinary excretion of TXB~2~ metabolites has been reported in the vast majority of patients with myeloproliferative neoplasms, such as essential thrombocythemia (ET) and polycythemia vera (PV) (reviewed by [@B62]). As shown in [**Figure 2**](#f2){ref-type="fig"}, the urinary excretion rates of 11-dehydro-TXB~2~ measured in untreated ET ([@B71]) and PV patients ([@B39]) are comparable to the rate measured in patients with unstable angina ([@B32]; [@B85]) and higher than values of metabolite excretion associated with a variety cardiovascular risk factors ([@B47]; [@B18]; [@B19]; [@B25]; [@B44]). The finding of persistently enhanced TXA~2~ biosynthesis in PV patients and its suppression by low-dose aspirin ([@B39]) provided a rationale for testing the efficacy and safety of this antiplatelet strategy in PV ([@B40]). Based on the positive results of the ECLAP (European Collaboration on Low-dose Aspirin in Polycythemia vera) trial ([@B40]), primary prophylaxis with low-dose aspirin (81--100 mg daily) is currently recommended for PV patients ([@B82]).

![Urinary excretion rates of 11-dehydro-TXB~2~ in clinical settings at high cardiovascular risk. Mean (± standard deviation) or median (interquartile range) urinary excretion rates of 11-dehydro-TXB~2~ in clinical settings characterized by high cardiovascular risk. PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; T2DM, type 2 diabetes mellitus; TIA, transient ischemic attack. Modified and redrawn from [@B62].](fphar-10-01244-g002){#f2}

Urinary 11-dehydro-TXB~2~ excretion has been investigated as a potential biomarker of the future risk of major vascular events in aspirin-treated, high-risk patients enrolled in the Heart Outcomes Prevention Evaluation (HOPE) trial, by using a nested case-control design ([@B27]). After adjustment for baseline differences, the odds for the composite end-point of myocardial infarction, stroke, or cardiovascular death increased with each increasing quartile of baseline urinary 11-dehydro-TXB~2~, with patients in the upper quartile having approximately 2-fold higher risk than those in the lower quartile ([@B27]). This finding was largely confirmed by a similar substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial ([@B28]). However, because both HOPE and CHARISMA were mostly secondary prevention trials, an important limitation of these analyses is represented by the lack of a control group of subjects not treated with aspirin. Furthermore, the extent of biological variation in urinary 11-dehydro-TXB~2~ excretion rate, as well as the intrasubject variability in its reduction by low-dose aspirin are currently unknown, but could potentially limit the value of this biomarker to predict the risk of future cardiovascular events in an individual aspirin-treated patient. We are currently investigating the potential predictive value of urinary 11-dehydro-TXB~2~ excretion in a large sample of A Study of Cardiovascular Events in Diabetes (ASCEND) that randomized 15,480 adults with diabetes mellitus to long-term treatment with low-dose aspirin or placebo ([@B3]).

Recently, the platelet origin of urinary thromboxane metabolite (TXM) excretion was challenged by the case report of a single patient with end-stage renal failure requiring dialysis who carried a rare genetic mutation in cPLA~2α~ (cytosolic phospholipase A~2~), resulting in dramatically reduced urinary TXM and PGI~2~ metabolite (PGIM) excretion rates, with recovery of "normal" urinary levels of these prostanoid metabolites after kidney transplantation ([@B45]). The authors' conclusion was that "urinary PGIM and TXM can be derived exclusively by the kidney without contribution from PGI~2~ made by endothelial cells or TXA~2~ by platelets in the systemic circulation" ([@B45]). However, the authors did not investigate the metabolic disposition of TXB~2~ and PGI~2~ in this patient, and no comparison was performed with renal failure and transplanted patients without the cPLA~2α~ genetic defect ([@B35]). Moreover, it should be emphasized that in patients with systemic lupus erythematosus, who displayed enhanced renal synthesis of TXA~2~, higher urinary TXB~2~ excretion was associated with unchanged urinary excretion of 2,3-dinor-TXB~2~ ([@B57]), suggesting that TXA~2~ produced by the kidney is mostly excreted unchanged into the urine and does not undergo systemic metabolism to TXM ([@B68]).

Serum TXB~2~ as a Validated Index of Platelet COX-1 Activity {#s3}
============================================================

The effects of aspirin on the activity of platelet COX-1 have been investigated through measurements of serum TXB~2~ ([@B55]; [@B51]) and urinary metabolites of TXB~2~ ([@B31]). Serum TXB~2~ reflects the maximal biosynthetic capacity of blood platelets to generate TXA~2~ in response to endogenously formed thrombin during whole-blood clotting, and its measurement has been used extensively to assess the human pharmacology of platelet COX-1 inhibition in health and disease (reviewed by [@B59]). Three important features of aspirin pharmacodynamics were characterized by measurements of serum TXB~2~ in healthy subjects ([@B51]): i) the cumulative nature of the inactivation of platelet COX-1 by repeated daily low doses (20--40 mg) of aspirin; ii) the saturability of this effect with single doses as low as 100 mg; and iii) the relative selectivity for platelet COX-1 inhibition at low doses. Our Research Group at the Catholic University School of Medicine in Rome described time-dependent, cumulative reduction in serum TXB~2~ (a product of platelet COX-1 activity), without statistically significant changes in urinary 6-keto-PGF~1α~ excretion (mostly a product of renal COX-2 activity), a reverse paradigm of selective COX-isozyme inhibition by low-dose aspirin (30 mg daily) in man ([@B51]) ([**Figure 3**](#f3){ref-type="fig"}). Measurements of serum TXB~2~ were also instrumental in characterizing the presystemic nature of platelet COX-1 acetylation by aspirin, an important feature of aspirin pharmacodynamics contributing to its biochemical selectivity ([@B63]). Thus, serum TXB~2~ was reduced by about 40% five min after the oral administration of a 20-mg dose, before aspirin could be detected in the systemic circulation ([@B63]).

![Long-term effects of low-dose (0.45 mg/kg per day) aspirin on platelet TXB~2~ and renal PGI~2~ synthesis. Serum TXB~2~ concentrations and urinary excretion of 6-keto-PGF~1α~ were measured in three healthy subjects before, during, and after aspirin therapy. Mean values ± SEM are plotted as percentage of control measurements performed prior to aspirin administration. The arrows indicate duration of daily aspirin therapy. Redrawn from [@B51].](fphar-10-01244-g003){#f3}

It is important to realize that the serum TXB~2~ assay requires almost immediate whole-blood incubation at 37°C as a condition for optimal thrombin generation, arachidonic acid release and its sequential conversion by platelet COX-1 and TX-synthase to form PGH~2~ and TXA~2~, respectively. As a consequence of thrombin-induced platelet activation, the blood concentration of TXB~2~ increases over 60 min from 1 to 2 pg/ml (true circulating plasma level *in vivo*) to 300 to 400 ng/ml (maximally stimulated, COX-1-dependent production *ex vivo*) ([@B55]). A variably delayed access to 37°C incubation, as well as different analytical methods to quantitate serum TXB~2~, may contribute to variable results in a multicenter setting ([@B33]; [@B69]). [@B64] investigated whether a variable delay in 37°C incubation and/or analytical discrepancies may affect the assessment of aspirin pharmacodynamics based on serum TXB~2~ determinations. They found that a longer than 5-min delay in the 37°C incubation of whole-blood samples may variably influence the assessment of platelet COX-1 inhibition by low-dose aspirin and confound the analysis of aspirin responsiveness in the clinical setting ([@B64]; [@B22]). In contrast, a GC/MS-validated immunoassay and liquid chromatography-tandem mass-spectrometry yielded quite comparable TXB~2~ concentrations in the same serum samples ([@B64]).

The relationship between inhibition of platelet COX-1 activity, as reflected by serum TXB~2~, and arachidonic acid-dependent platelet function assays (i.e., arachidonate-induced optical aggregation), and urinary 11-dehydro-TXB~2~ excretion is strikingly non-linear ([**Figure 4**](#f4){ref-type="fig"}) ([@B67]; [@B78]). Thus, platelet COX-1 activity must be nearly completely (\>97%) suppressed to fully inhibit *in vivo* platelet activation. Such stringent requirement may help explain the fact that the vast majority of traditional nonsteroidal antiinflammatory drugs (tNSAIDs), that are reversible inhibitors of platelet COX-1 with variable half-lives, are unable to achieve profound and persistent suppression of TXA~2~ biosynthesis, thereby unmasking their COX-2--dependent cardiovascular toxicity (reviewed by [@B54]). Although the variable COX-isozyme selectivity, half-life, daily dose, and duration of treatment of different COX-2 inhibitors could all influence the cardiovascular consequences of COX-2 inhibition, the dichotomous clinical read-outs of such inhibition are explained by the exponential relationship between inhibition of platelet COX-1 activity and suppression of TXA~2~-dependent platelet activation ([**Figure 4**](#f4){ref-type="fig"}) ([@B54]). As depicted in [**Figure 4**](#f4){ref-type="fig"}, NSAIDs inhibiting platelet COX-1 activity by 0% to 20% (e.g., highly selective COX-2 inhibitors, such as rofecoxib and etoricoxib), by 20% to 50% (e.g., COX-2 inhibitors with moderate COX-2 selectivity, such as diclofenac and celecoxib), or by 50% to 90% (most tNSAIDs, such as indomethacin and ibuprofen) will cause similarly modest suppression of TXA~2~-dependent platelet activation *in vivo* ([@B54]). Due to its longer half-life and modest COX-1 selectivity, naproxen 500 mg twice daily may suppress platelet COX-1 activity by \>95% throughout the 12-h dosing interval and reduce TXA~2~-dependent platelet activation *in vivo* to a similar extent as aspirin 100 mg once daily ([@B11]; [@B12]).

![Nonlinear relationship between inhibition of serum thromboxane (TX) B~2~ and urinary 11-dehydro-TXB~2~ excretion. In the lower left panel, individual percentage inhibition values are depicted from all on-treatment and post-treatment measurements performed in 48 healthy subjects randomized to receive aspirin 100 mg daily for 1 to 8 weeks. The nonlinear relationship between percent inhibition of serum TXB~2~ and urinary 11-dehydro-TXB~2~ showed that for 0 to 97% of COX-1 inhibition, TXA~2~ biosynthesis *in vivo* was linearly inhibited by \<40% and that \>97% suppression of serum TXB~2~ was necessary to maximally reduce TX metabolite (TXM) excretion. The upper right panel represents a detail of the left panel and is based on mathematical modeling of the experimental data. Modified and redrawn from [@B78], with permission from the publisher.](fphar-10-01244-g004){#f4}

Given the non-linear relationship depicted in [**Figure 4**](#f4){ref-type="fig"}, platelet function assays, including urinary 11-dehydro-TXB~2~, do not accurately reflect the degree of platelet COX-1 inhibition ([@B50]; [@B80]). Moreover, platelet function assays routinely used to measure aspirin response, are not necessarily related to its mechanism of action, display poor inter-assay agreement ([@B41]; [@B7]; [@B78]; ), and give inconsistent results upon repeated measurements ([@B46]; [@B78]). These methodological considerations may help explain the rise and fall of the aspirin "resistance" concept, typically defined as impaired platelet response to aspirin based on a single functional measurement performed at an often unspecified time point after dosing, usually without a reliable assessment of compliance ([@B43]; [@B72]). In a study of 48 healthy volunteers, repeated measurements of platelet aggregation in response to different agonists demonstrated that occasionally "resistant" subjects could be classified as "responders" when examined previously or subsequently ([@B78]). Not surprisingly, the incidence of "resistance" ranged from 1% up to 65% in different studies, was assay-dependent, fluctuated over time, and remains of unproven clinical significance (reviewed by [@B60]).

In contrast to the uniform effectiveness of low-dose aspirin in suppressing platelet COX-1 activity in healthy individuals, some clinical conditions are associated with transient or persistent suboptimal platelet inhibition by a conventional once daily regimen of low-dose aspirin ([@B72]). These include patients following on-pump coronary artery bypass surgery (CABG) ([@B13]), patients with ET ([@B26]; [@B23]), patients with coronary artery disease and the metabolic syndrome ([@B80]), and some patients with type-2 diabetes mellitus ([@B81]; [@B74]; [@B6]). Under these circumstances, most patients display biochemical evidence of TXA~2~-dependent platelet activation *in vivo* ([@B18]; [@B71]), a finding that may help explain impaired aspirin pharmacodynamics. More specifically, less-than-optimal inactivation of platelet COX-1 could be a consequence of transiently ([@B13]) or persistently ([@B26]) accelerated platelet renewal, or result from platelet activation-induced generation of hydroperoxides that may impair the acetylation of COX-1 by aspirin ([@B5]). The long-lasting duration of the antiplatelet effect of aspirin, despite its very short half-life, is explained by inactivation of COX-1 in bone-marrow platelet progenitors, as reflected by the 48-h delay between aspirin withdrawal and initial recovery of unacetylated COX-1 ([@B10]) and TXA~2~ biosynthetic capacity ([@B51]) in peripheral blood platelets. Thus, under conditions of normal thrombopoiesis, the efficacy of a short-lived drug given once daily reflects irreversible inactivation of a slowly renewable drug target (platelet COX-1) combined with an effect on bone-marrow platelet progenitors, leading to a new platelet progeny with largely non-functioning COX-1 for the vast majority of the 24-h dosing interval ([@B34]). However, reduced systemic bioavailability of aspirin, as may occur with some enteric-coated formulations ([@B42]) and in association with obesity ([@B65]), or faster renewal of platelet COX-1, as reported under conditions of altered megakaryopoiesis ([@B50]), may shorten the duration of the antiplatelet effect of aspirin and dictate a more frequent dosing regimen ([@B62]).

A standard once-daily regimen of low-dose aspirin administration cannot adequately suppress platelet TXA~2~ production, throughout the 24-h dosing interval, in the vast majority of ET patients ([@B26]; [@B23]; [@B50]). An accelerated turnover of platelet COX-1, reflecting abnormal megakaryopoiesis, has been hypothesized in ET ([@B50]; [@B73]; [@B34]). A higher daily fraction of newly released platelets with unacetylated COX-isozymes would account for incomplete inhibition, as well as time-dependent recovery of TXA~2~-dependent platelet function during the standard 24-h dosing interval of low-dose aspirin administration ([@B26]). Two relatively small studies in ET patients have shown that sub-optimal inhibition of platelet TXA~2~ production and TXA~2~-dependent platelet function can be largely rescued by a bid regimen of low-dose (100 mg) aspirin administration, but not by a higher dose (200--250 mg) given once daily ([@B24]; [@B50]). The Aspirin Regimens in Essential Thrombocythemia Study (ARES) is a randomized, parallel-arm, dose-finding study recruiting 300 ET patients to address two main questions ([@B22]). First, whether a bid or tid 100-mg aspirin regimen is more effective than the standard once daily regimen in inhibiting platelet TXA~2~ production, without a major impact on vascular PGI~2~ biosynthesis. Second, whether superior biochemical efficacy of a multiple versus single dosing low-dose aspirin regimen can be safely maintained over long-term follow-up ([@B22]).

Similarly, several independent studies have consistently shown the superior biochemical efficacy of a strategy based on shortening the dosing interval versus a strategy of maintaining or increasing the once daily dose of aspirin in patients with type-2 diabetes mellitus ([@B81]; [@B74]; [@B6]), undergoing CABG ([@B48]; [@B13]), or presenting with an acute coronary syndrome ([@B49]).

Obesity is associated with biochemical evidence of persistently enhanced platelet activation ([@B20]; [@B65]) and high risk of atherothrombotic complications (reviewed by [@B75]). Recently, [@B77] analyzed individual data of 117,279 subjects recruited into 10 primary prevention trials and reported that low doses of aspirin (75--100 mg) were only effective in preventing major vascular events in subjects with body weight lower than 70 kg, and had no benefit in the vast majority of men and nearly 50% of all women weighing 70 kg or more. In contrast, higher doses (≥ 325 mg) of aspirin were only effective in subjects with body weight equal to or higher than 70 kg ([@B77]). Although the finding of effect modification by body weight has not been confirmed by some of the more recent aspirin trials ([@B3]), these data appear consistent with the suggestion that the antiplatelet effect of aspirin, as reflected by serum TXB~2~ measurement, is influenced by body size ([@B42]). Increased body size, fat excess, and the associated changes in volume of distribution and liver function may all reduce the bioavailability of a lipophilic drug such as aspirin ([@B61]). [@B65] recently reported measurements of serum TXB~2~ at the end of the 24-h dosing interval in 100 aspirin-treated subjects with a wide range of body mass index (BMI) and body weight values. A statistically significant exponential association was observed between body size, expressed as either BMI or body weight, and residual serum TXB~2~ values ([**Figure 5**](#f5){ref-type="fig"}) ([@B65]). Thus, a standard, once‐daily 100-mg aspirin regimen appears to be inadequate to fully inhibit platelet COX‐1 activity throughout the 24-h dosing interval in moderately to severely obese subjects. However, based on the data depicted in [**Figure 5**](#f5){ref-type="fig"}, one would not expect impaired aspirin pharmacodynamics in subjects with up to a body weight of ∼100 kg or a BMI of 35 kg/m^2^, corresponding to obesity of class 2 or higher ([@B65]). *In silico* modeling of the antiplatelet pharmacodynamics of aspirin in this setting suggested that either doubling the once‐daily dose or administering a lower dose (e.g., 85 mg) twice daily would be associated with adequate suppression of platelet TXA~2~ production([@B65]). The consensus opinion that "it is reasonable to double the daily dose or shorten the dosing interval (twice-daily) for BMI ≥ 40 kg/m^2^" expressed by the Working Group on Thrombosis of the European Society of Cardiology ([@B75]) is consistent with these experimental findings and *in silico* modeling ([@B65]).

![Serum thromboxane (TX)B~2~ levels at 24 h after aspirin intake (100 mg once daily) vs body mass index or body weight. Log-transformed serum TXB~2~ levels measured 24 h after a witnessed aspirin intake are represented in relation to body mass index (panel **A**) and body weight (panel **B**). Triangles represent individual patients receiving aspirin for primary or secondary cardiovascular prevention, n = 71; circles represent individual healthy subjects, n = 25. Solid lines and green areas: predicted serum TXB~2~ levels and 95% confidence intervals, respectively, as a function of increasing body mass index (panel **A**) and body weight (panel **B**) in the 96 study subjects. Horizontal dotted lines were drawn to indicate serum TXB~2~ levels of 3, 6, and 9 ng/mL, corresponding to 99%, 98%, and 97% inhibition of platelet COX-1 activity, respectively, measured in healthy subjects. The vertical dotted lines were drawn to indicate on the abscissa scales the highest calculated values of body mass index (panel **A**) and body weight (panel **B**) compatible with these different levels of platelet COX-1 inhibition. Modified and redrawn from [@B65], with permission from the publisher.](fphar-10-01244-g005){#f5}

Clinical Implications and Perspective {#s4}
=====================================

If we look back at four decades of research on thromboxane biosynthesis and inhibition, the translational aspect of this research stands out in at least three areas. First, measurements of urinary TXM excretion, a non-invasive index of *in vivo* platelet activation, have been instrumental in identifying clinical conditions in which to assess the efficacy and safety of antiplatelet therapy. Notable examples are represented by acute coronary syndromes ([@B32]), acute ischemic stroke ([@B38]), and polycythemia vera ([@B39]). The remarkable cardio-protective effects of low-dose aspirin in these settings ([@B83]; [@B40]; [@B76]) are likely to reflect the important pathophysiologic role of transiently or persistently enhanced platelet activation unravelled by TXM measurements. Second, the development of serum TXB~2~ as a mechanism-based biomarker of platelet COX-1 inhibition ([@B55]) has played a fundamental role in defining the human pharmacology of aspirin as an antiplatelet agent ([@B53]). The results of a large series of randomized, placebo-controlled clinical trials of aspirin in the prevention of atherothrombosis in high-risk patients have confirmed the saturability of its antithrombotic effect at low doses ([@B2]), consistent with saturability of platelet COX-1 inactivation by low-dose aspirin ([@B51]; [@B31]). Third, a comparison of the extent and duration of serum TXB~2~ reduction in response to different NSAIDs has allowed predicting a similar cardiovascular hazard of tNSAIDs and coxibs ([@B4]): "If the vascular consequences of endothelial COX‐2 inhibition are modulated by profound and persistent blockade of platelet COX‐1 activity, as indirectly implied by genetic and pharmacologic manipulations in mice ([@B14]), then the cardiovascular effects of most traditional NSAIDs, which only incompletely and transiently inhibit platelet COX‐1, may resemble those of selective COX‐2 inhibitors." A prediction largely borne out by a tabular data meta-analysis published in 2006 ([@B37]) and substantiated by an individual participant data meta-analysis of coxib and tNSAID trials in 2013 ([@B17]).

Finally, as anticipated in the 1982 *Journal of Clinical Investigation* paper, "since the effect of low-dose aspirin is dependent upon platelet turnover as well as aspirin sensitivity of platelet and megakaryocyte cyclooxygenase, the adequacy of this therapeutic regimen might vary in different disease states" ([@B51]). More recent studies based on this methodological approach have largely confirmed this prediction both in specific clinical settings and by *in silico* modelling. Altogether, early and newer evidences have shown the desirability and practicality of adjusting the aspirin dosing interval based on two measurements of serum TXB~2~ at 12 and 24 h after dosing ([@B50]; [@B74]), a personalized approach that may be required under conditions of reduced systemic bioavailability of aspirin ([@B65]) or enhanced platelet turnover ([@B62]).
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